Sooma

Executive Summary

Sooma is a Finnish digital health company specializing in transcranial direct current stimulation (tDCS) for treating depression and chronic pain. The company holds the distinction of being the first and only system with EU MDR approval, underscoring its regulatory compliance and safety standards. Founded in 2013 and based in Helsinki, Sooma addresses a significant unmet need for non-invasive, accessible brain stimulation therapies that can reduce patient queues and improve care efficiency. Its tDCS platform offers an easy-to-use solution for clinicians, potentially transforming outpatient management of major depressive disorder and chronic pain conditions. Although financial details are undisclosed, the company's validated regulatory pathway positions it favorably for commercialization across Europe and beyond. Sooma operates at the intersection of digital health and neuroscience, targeting a growing market for neuromodulation therapies. With an aging population and rising prevalence of mental health disorders, demand for effective, side-effect-free alternatives to pharmaceuticals is increasing. The company's competitive advantage lies in its MDR certification, which may expedite adoption in European healthcare systems. Upcoming catalysts include potential expansion into additional indications such as anxiety or Parkinson's disease, strategic partnerships with hospitals or telemedicine platforms, and reimbursement approvals in key European markets. These events could drive revenue growth and validate the platform's clinical utility. However, the company faces competition from other tDCS players and must demonstrate robust real-world evidence to achieve widespread uptake.

Upcoming Catalysts (preview)

• Q3 2026New clinical trial results for additional indications (e.g., anxiety or fibromyalgia)60% success
• TBDReimbursement approval in a major European market (e.g., Germany or France)50% success
• TBDStrategic partnership with a large healthcare provider or digital health platform70% success